1stOncology™: Cancer Intelligence Service – Page 819 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Imbrium Therapeutics to Showcase Pipeline Assets Open for Partnership at the BIO International Convention 2025

On June 16, 2025 Imbrium Therapeutics L.P. ("Imbrium"), a clinical-stage biopharmaceutical company, reported pipeline developments at the BIO International Convention on Wednesday, June 18, at 9:15 a.m. in Room 153B (Press release, Imbrium Therapeutics, JUN 16, 2025, View Source [SID1234653936]). Imbrium is actively seeking partnerships to advance the development of investigational therapeutics for multiple indications across several disease areas including genitourinary disorders, substance use disorders, and cancerous malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Imbrium is discussing two investigational agents, sunobinop and tinostamustine, both of which could present substantial revenue opportunities*.

Sunobinop is a novel, first-in-class, nociceptin receptor partial agonist. The orally active investigational drug is in Phase 1b/2a clinical development for multiple indications, including alcohol use disorder (AUD), interstitial cystitis/bladder pain syndrome (IC/BPS), and overactive bladder (OAB). Related to AUD, sunobinop’s pharmacological properties offer a unique approach under investigation for alcohol craving, consumption and sleep issues; it has the potential to be the first new modality in AUD in almost 20 years. Related to OAB and IC/BPS, sunobinop has been shown in early studies to target the sensory nerves in the bladder to affect urination, pain, and nocturia. Global or regional rights are available for partnership.

Tinostamustine is a novel, first-in-class, investigational drug combining DNA alkylating activity and histone deacetylase inhibition in a single molecule. It has the potential to be a first-line agent to treat patients with glioblastoma multiforme (GBM), a highly aggressive form of brain cancer. In Phase 1 studies as an adjuvant to standard chemoradiation, tinostamustine was shown to improve survival in difficult-to-treat newly diagnosed patients and is on track for accelerated development. It has the potential to be the first new chemotherapeutic to treat GBM in more than 20 years. Tinostamustine has also shown promise in early clinical studies in other solid and hematological tumors. U.S. rights are available for partnership.

"We are committed to securing partnerships that further advance promising novel therapies," said David Saussy, Head of Licensing & Business Development. "We look forward to presenting these pipeline highlights at BIO and moving our research programs forward to help address unmet patient needs."

Tinostamustine and all proposed indications for sunobinop are open to partnering. For more information, e-mail [email protected]. For more information about our pipeline, click here.

*This release discusses investigational uses of agents in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that sunobinop or tinostamustine will successfully complete development or gain FDA approval.

Solu Therapeutics Appoints Enda Moran, PhD, MBA as Chief Operating Officer

On June 16, 2025 Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, reported the appointment of Enda Moran, PhD, MBA as Chief Operating Officer (COO) (Press release, Solu Therapeutics, JUN 16, 2025, View Source [SID1234653935]).

"As we advance our Phase 1 clinical trial of STX-0712 in patients with resistant/refractory chronic myelomonocytic leukemia (CMML) and other hematologic malignancies, Enda brings outstanding experience in large-scale biomanufacturing and company operations to our leadership team," said Philip J. Vickers, President and CEO of Solu Therapeutics. "His expertise in scaling biologic therapeutics and guiding early-stage programs through development will be instrumental as we grow and work to deliver transformative therapies for patients living with cancer, immunological diseases and other serious illnesses."

As COO, Dr. Moran will lead core operational functions at Solu including chemistry manufacturing and controls (CMC), quality, program management, IT, and facilities management. He will also play a key role in building the infrastructure needed to support Solu’s CyTAC (Cytotoxicity Targeting Chimera) and TicTAC (Therapeutic Index Control Targeting Chimera) platforms as the company progresses toward multiple clinical and regulatory milestones.

"I am very excited to join the Solu Therapeutics team at this pivotal moment as the company moves into a new phase of growth," said Dr. Moran. "The CyTAC and TicTAC platforms are rooted in strong science and have the potential to change the landscape for patients who are desperately in need of new treatment options. I look forward to applying my experience to maximize the potential of these platforms and bring a new generation of innovative therapies to the patients who need them most."

Dr. Moran has over three decades of experience leading biomanufacturing and technical development across pharma and biotech. He previously held senior scientific roles at GSK and Wyeth before joining Pfizer as Senior Director of Biomanufacturing, where he led global teams supporting the development and production of successful commercial therapies including Enbrel, Trumenba, Xyntha, and the Prevnar13 vaccine. He later joined Northern Biologics as Vice President and Head of CMC and Manufacturing, where he was instrumental in advancing multiple development programs and enabling the strategic acquisition of assets by AstraZeneca and Boehringer Ingelheim. Most recently, he served as CEO of Matrivax, leading a successful corporate restructuring and completion of a Phase 1 clinical trial.

ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)

On June 16, 2025 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), reported updated data from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be presented during a poster session at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20 (Press release, ADC Therapeutics, JUN 16, 2025, View Source [SID1234653934]). These data will be made available online beginning on Wednesday, June 18, at 8:30 a.m. CEST. The single-arm, open-label, study is led by Izidore S. Lossos, MD, Chief, Division of Hematology Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

"These updated results further support the potential of ZYNLONTA as an effective single-agent treatment for patients with r/r MZL, including high-risk POD24 patients," said Lossos, the study’s principal investigator. "Importantly, the treatment was generally well tolerated, with manageable safety consistent with the known profile."

As of February 10, 2025, a total of 27 adult patients with r/r MZL and previously treated with ≥1 line of systemic therapy were enrolled with 26 patients evaluable for response. Highlights of the data include:

Overall response rate (ORR) of 84.6% (22/26); complete response (CR) rate of 69.2% (18/26)
Among POD24 patients assessed for response, a CR rate of 61.5% (8/13) was observed
CR was maintained in 17 of 18 CR patients who achieved CR, with longest duration of CR of 27 months from start of treatment
Progression-free survival (PFS) was 92.9% at 12 months
27 enrolled patients experienced adverse events (AE), consistent with the known safety profile of ZYNLONTA and most commonly grade 1 or 2. Grade 3 and 4 AEs were observed in 16 and 2 patients, respectively and included neutropenia, RSV lung infection and hyponatremia (with 2 AEs occurring in the same patient). Three patients needed dose reduction and one patient discontinued treatment after cycle 4 due to cholestatic hepatitis that fully recovered.
The study is being conducted at Sylvester Comprehensive Cancer Center and at City of Hope, and recently expanded to Emory Winship Cancer Institute and Vanderbilt-Ingram Cancer Center to accelerate enrollment to 50 patients with r/r MZL. More details on this ongoing Phase 2 clinical trial can be found at View Source (identifier: NCT05296070).

"Based on the updated Phase 2 IIT data to be shared at ICML, we are encouraged by the potential opportunity in r/r MZL and look forward to seeing additional data, as the trial expands to other sites." said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. "As this trial progresses, assuming the results continue to be positive, we plan to potentially pursue a regulatory pathway and compendia in parallel as soon as sufficient data are available."

In addition to the MZL poster presentation at ICML, an oral encore presentation of the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) will also be presented at ICML Friday, June 20 at 3:00 p.m. CEST.

About ZYNLONTA

ZYNLONTA is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The potent payload binds to DNA minor groove with little distortion, remaining less visible to DNA repair mechanisms. This ultimately results in cell cycle arrest and tumor cell death.

The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved ZYNLONTA (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from low-grade lymphoma and also high-grade B-cell lymphoma. The trial included a broad spectrum of heavily pre-treated patients (median three prior lines of therapy) with difficult-to-treat disease, including patients who did not respond to first-line therapy, patients refractory to all prior lines of therapy, patients with double/triple hit genetics and patients who had stem cell transplant and CAR-T therapy prior to their treatment with ZYNLONTA. This indication is approved by the FDA under accelerated approval and in the European Union under conditional approval based on overall response rate and continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Please see full prescribing information including important safety information about ZYNLONTA at www.ZYNLONTA.com.

ZYNLONTA is also being evaluated as a therapeutic option in combination studies in other B-cell malignancies and earlier lines of therapy.

BioDlink’s Bevacizumab Approved for Market Launch in Nigeria, Accelerating Global Expansion

On June 16, 2025 BioDlink reported that its self-developed Bevacizumab Injection (Pusintin) has received marketing approval from National Agency for Food and Drug Administration and Control (NAFDAC) of Nigeria (Press release, Tot Biopharm, JUN 16, 2025, View Source [SID1234653933]). This significant milestone accelerates BioDlink’s global expansion efforts, and reaffirms its R&D and commercialization strength in biosimilar—offering a high-value, accessible treatment option for cancer patients worldwide.

Leveraging synergies with Kexing BioPharm, the global licensee for Pusintin in emerging markets, Pusintin has initiated regulatory filings in 35 countries. The approval in Nigeria not only marks the implementation of its global strategy but also signifies officially opening the door to the African market, bringing more affordable treatment alternatives to Nigerian patients.

ADDRESSING AFRICA’S GROWING HEALTHCARE NEEDS

Africa, with a population exceeding 1.5 billion (World Bank, 2024), faces increasing medical demand. Nigeria, as the "most populous country in Africa" (~220 million people), possesses both massive healthcare challenge and a major growth opportunity. According to the World Health Organization (WHO), Nigeria reports over 120,000 new cancer cases annually, growing at a rate of 5% per year—amid limited access to high-quality therapies. Pusintin’s approval meets this urgent medical need while serves as a model for expansion into other emerging-market.

INTERNATIONALLY RECOGNIZED MANUFACTURING & QUALITY EXCELLENCE

The approval has validated Pusintin’s compliance complies with international standards for R&D, manufacturing, and quality system. BioDlink’s production facilities have already passed GMP inspections in China, Japan, Brazil, Colombia, Egypt, Indonesia, and Argentina and also passed antibody drug and ADC EU QP inspection 4 times in past two years. BioDlink’s global-quality system ensures robust commercial supply, delivering more than 100 clinical projects with development, clinical filings, and manufacturing services worldwide, including European and the U.S. in the past 3 years.

This millstone marks the beginning of BioDlink’s international commercial rollout, injecting new momentum into its revenue diversification strategy and reinforcing its capabilities in global biosimilar commercialization.

BioDlink operates a large-scale, GMP-compliant biologics manufacturing facility, featuring four commercial lines with five drug substance production centers (including non-toxic conjugated drug substance units) and four drug production centers. Its world-class facilities and stringent quality system deliver reliable global supply for monoclonal antibodies (mAbs), bispecific antibodies, XDCs, and other biologics at global standards.

SUSTAINING GLOBAL MOMENTUM

BioDlink will continue collaborating with Kexing BioPharm to accelerate Pusintin’s approval in Southeast Asia and Latin America. Driven by a committed to innovation, quality, and global compliance, BioDlink will continue accelerating its expansion in overseas and emerging markets—bringing life-changing therapies to more patients worldwide.

Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241

On June 16, 2025 Pierre Fabre Laboratories reported the acquisition from Antares Therapeutics, Inc. ("Antares"), a spin-out of Scorpion Therapeutics, Inc., of the worldwide rights for PFL-721 and PFL-241 (formerly known as STX-721 and STX-241, respectively) (Press release, Pfizer, JUN 16, 2025, View Source [SID1234653932]). Under the terms of the agreement, Pierre Fabre Laboratories will expand its previous agreement with Scorpion Therapeutics to hold the global rights for both assets and will be leading the clinical development of both programs.

PFL-721 is a mutant-specific EGFR exon 20 and HER2 exon 20 inhibitor, soon to transition to dose optimization within a first-in-human trial in NSCLC. PFL-241 is a mutant-specific, brain penetrant, 4th generation EGFR inhibitor, currently in dose escalation in a first-in-human trial, to address C797S resistance mutations in NSCLC patients.

NSCLC is the most common sub-type of lung cancer and various EGFR mutations are the most frequent drivers of NSCLC, occurring in approximately 14-38 percent of tumors, depending on geography.[1], [2], [3]

"With this agreement with Antares, Pierre Fabre Laboratories now own the global rights for all the assets within our R&D portfolio: exarafenib, PFL-002 (formerly VERT-002), PFL-721 and PFL-241. The R&D team is fully engaged and committed to progress the clinical development of these programs, aiming at providing novel and differentiated precision medicines to patient populations with significant unmet needs." said Francesco Hofmann, Head of Research and Development for Medical Care at Pierre Fabre Laboratories.